Circulating Tumor Dna to Monitor Treatment Response and Resistance in Mantle Cell Lymphoma

Abstract

Many cancers shed small amounts of DNA into the patient’s bloodstream. Recent advances in genomic technologies now allow small levels of cancer DNA to be accurately measured in the peripheral blood. Changes in DNA levels have the potential to be used as specific markers of disease progression and/or response to cancer therapy. This project will evaluate if this DNA can be measured from a simple blood test to serially follow patients receiving treatment for mantle cell lymphoma.

Related publications (1)

Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

R Agarwal, YC Chan, CS Tam, T Hunter, D Vassiliadis, CE Teh, R Thijssen, P Yeh, SQ Wong, S Ftouni, EYN Lam, MA Anderson, C Pott, O Gilan, CC Bell, K Knezevic, P Blombery, K Rayeroux, A Zordan, J Li

2019-01-01

Ibrutinib plus venetoclax is a highly effective combination in mantle cell lymphoma. However, strategies to enable the evaluation ..